In addition, a Kaplan-Meier analysis showed that higher SHMT2 expression was implicated in poorer progression-free survival (PFS) and overall survival (OS), although the data failed to link the expression of SHMT2 with drug resistance mechanisms in glioma patients 30, 31. This evidence concerns the gene SHMT2 and central nervous system cancer.